If these findings are confirmed by a prospective multicentre trial, which is expected in light of the provided data, it is reasonable that the proposed hormone immunotherapy can also be tested in the adjuvant setting of ER+, HER2- breast cancer patients with a high risk of relapse. Here, ESR1 is linked to breast cancer.